FRANKLIN LAKES, N.J., Aug. 25, 2015 /PRNewswire/ — BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc. BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices. The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of […]
Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical, will acquire the biopharmaceutical contract development manufacturing organization Cytovance® Biologics for $205.68 million cash plus additional contingent payments, Cytovance said today. The deal adds a CDMO to Hepalink’s U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredients (APIs). […]
THE HAGUE, Netherlands (AP) — Dutch nutritional supplements and chemicals company Royal DSM NV says it is laying off between 900 and 1,100 staff worldwide as part of a reorganization of its businesses. The company announced the job cuts Tuesday, saying the move would cut costs by 125-150 million euros ($144-173 million) by the end […]
Biopharmaceutical giant Amgen has opened its new €300m facility in Dun Laoghaire, following a five-year revamp job of the old Pfizer building. The development included the construction of an 11,500sqm production plant and a 5,800sqm cold chain warehouse – there was also significant refurbishment on buildings that already existed onsite, with total employment numbers there […]
No pain, no gain. Shareholders in Gilead Sciences (GILD 6.78%) may want to repeat that workout mantra as they watch markets slide. True, Gilead has taken some lumps. It was down 2% at one point Monday and is off about 9% over the past five trading days. The Nasdaq Biotechnology Index, meanwhile, is down about […]
Prominent hedge fund manager Kyle Bass’s campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc’s flagship multiple sclerosis drug, Ampyra. The decision to reject a review of the patents’ validity comes as the pharmaceutical industry […]
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]
San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities. Medivation will pay BioMarin $410 […]
On Aug. 20, 2015, Google Inc., soon to become Alphabet, announced on its blog that the first company to stand alone under Alphabet will be Google X’s Life Sciences. Writing on the blog, Sergey Brin, Google co-founder, said, “I am delighted to announce that the life sciences team is now ready to graduate from our […]